Latest Hotspot

Sarepta's EMERGENE Phase 3 Trial on SRP-9003 for LGMD 2E/R4 Begins Participant Enrollment

22 January 2024
3 min read

Sarepta Therapeutics, Inc., a pioneering company in the field of targeted genetic treatments for uncommon illnesses, has declared that participant selection has commenced for the clinical trial titled SRP-9003-301. Referred to as EMERGENE, the 9003-301 trial is a Stage 3 global clinical trial with an open-label design that is evaluating SRP-9003 (bidridistrogene xeboparvovec) in patients suffering from limb-girdle muscular dystrophy Type 2E, also known as beta sarcoglycanopathy.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

We are delighted to convey the ongoing advancements we've made with SRP-9003, an uncommon LGMD that currently lacks comprehensive treatment options beyond simply addressing symptoms. Preliminary outcomes from the trials of SRP-9003 have shown substantial levels of protein synthesis occurring at the 12-week mark and persisting for up to two years post-administration, alongside observable improvements in patient function that help decelerate the disease's advancement,” explained Louise Rodino-Klapac, Ph.D., the senior vice president and principal scientific leader with the added responsibility of overseeing research and development at Sarepta Therapeutics.

Dr. Rodino-Klapac added, “Beyond the direct impact for patients with LGMD2E, the EMERGENE initiative is set to provide valuable insights for the clinical strategy of additional LGMD projects within the portfolio of Sarepta Therapeutics. It also paves the way for establishing effective regulatory strategies that could accelerate the approval processes for gene therapies aiming to address extremely rare diseases.”

The investigational gene therapy SRP-9003, also known as bidridistrogene xeboparvovec, harnesses the AAVrh74 vector for its administration, which has been tailored for systemic and effective delivery to the skeletal, diaphragmatic, and heart muscles, rendering it an optimal therapeutic agent for various muscular conditions. SRP-9003's design includes the transfer of a complete beta-sarcoglycan gene and is driven by the MHCK7 promoter, a promoter selected for its demonstrated strength in cardiac expression.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of January 19, 2024, there are 1 investigational drugs for the SGCB target, including 2 indications, 3 R&D institutions involved, with related clinical trials reaching 2, and as many as 357 patents.

MYO-101 targets the SGCB gene and is primarily indicated for Limb-Girdle Muscular Dystrophy, Type 2E. However, its therapeutic areas suggest potential applications in various diseases affecting the nervous system, musculoskeletal system, skin, cardiovascular system, and respiratory system. With its current status in Phase 2, MYO-101 shows promise in the field of biomedicine for the treatment of these conditions.

图形用户界面, 文本, 应用程序

描述已自动生成

Exploring the Latest ETA Antagonists Deal by SanReno Therapeutics: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
3 min read
Exploring the Latest ETA Antagonists Deal by SanReno Therapeutics: A Guide to Rapidly Accessing Transaction Insights
22 January 2024
Novartis Pharma will purchase SanReno Therapeutics, enhancing its kidney treatment range. Following the acquisition, SanReno will join Novartis China, advancing clinical trials of two important IgA nephropathy treatments, atrasentan and BION-1301.
Read →
CARsgen's CT011 Granted NMPA Clearance for Phase IIIa Liver Cancer Trial
Latest Hotspot
3 min read
CARsgen's CT011 Granted NMPA Clearance for Phase IIIa Liver Cancer Trial
22 January 2024
CARsgen's candidate, CT011, has secured authorization from the NMPA to proceed with trials for GPC3-positive Ⅲa hepatocellular carcinoma patients with a significant risk of recurrence post-surgery.
Read →
Who submits information about a clinical study to the ClinicalTrials.gov database?
Knowledge Base
2 min read
Who submits information about a clinical study to the ClinicalTrials.gov database?
22 January 2024
The sponsor of a clinical trial, which may be a pharmaceutical company or an academic institution, is responsible for submitting information about their study to the ClinicalTrials.gov database.
Read →
Roche's Tecentriq® with ENHANZE® Tech Gets EU Clearance for Subcutaneous Use in Cancer Therapy
Latest Hotspot
3 min read
Roche's Tecentriq® with ENHANZE® Tech Gets EU Clearance for Subcutaneous Use in Cancer Therapy
22 January 2024
Halozyme Reports Roche Granted EU Clearance for Subcutaneous Form of Tecentriq® with ENHANZE® Technology, Marking a Breakthrough in the Delivery of Immunotherapies Across Various Cancers.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.